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Abstract: Azilsartan–chlorthalidone fixed combination is a new drug in the management 
of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects 
than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of 
  chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique 
because it is the first to partner an ARB with this, possibly more effective, diuretic. This review 
will address trials involving both components of this drug, as well as phase III trials involving 
the fixed-combination product. The article will also discuss the benefit of combination therapy 
in the treatment of hypertension.
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Introduction
Despite the knowledge gained from large clinical trials, cardiovascular disease remains 
one of the leading causes of death, and hypertension remains a significant cause of 
cardiovascular morbidity and mortality. According to the National Heart, Lung, and 
Blood Institute, over one-third of the United States was diagnosed with hypertension 
during 2005–2008. Fortunately, over 70% of these patients were being treated for their 
hypertension, but disappointingly only 47.7% had controlled blood pressure (BP).1 
This lack of medical success is one reason why new antihypertensive agents continue 
to be developed and also explains the interest in fixed-combination antihypertensive 
agents, such as the new angiotensin-receptor blocker/thiazide-type combination of 
azilsartan–chlorthalidone.
The current guidelines recommend administering more than one drug as initial 
therapy for BP .20 mmHg systolic or .10 mmHg diastolic above goal, with one of 
these drugs being a thiazide-type diuretic.2 Angiotensin-receptor blockers (ARBs) as 
initial therapy have also fallen into favor due to their cardiovascular morbidity and 
tolerability benefits over beta blockers.3 Several trials have shown that combination 
therapy increases achievement of BP control at lower doses which also decreases side 
effects.4–6 When using combination therapy, fixed-combination agents have the benefit 
of also increasing efficacy by increasing compliance.4
Several fixed-combination antihypertensive agents exist, and seven of them are 
prescribed enough to be on the top 200 drugs list.7 Azilsartan–chlorthalidone is unique 
in that it is the only combination drug that contains an ARB with the long-acting 
thiazide-type diuretic, chlorthalidone.8 This article will discuss the clinical utility of 
fixed-combination azilsartan–chlorthalidone in the management of hypertension.
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Azilsartan: a new ARB
Angiotensin II (AngII) is an integral hormone in the regula-
tion of BP. AngII causes most of its hypertensive effects by 
stimulating the angiotensin type I receptor (AT1), making 
this receptor the primary target of ARBs. When activated, 
AT1 results in hypertension from direct vasoconstriction 
and secretion of aldosterone, and central AngII has also 
been shown to affect regulation of the sympathetic nervous 
system.9 ARBs have shown their value in BP therapy by 
being as efficacious as angiotensin-converting enzyme (ACE) 
inhibitors, while causing fewer side effects than other drug 
classes, including idiosyncratic cough and angioedema asso-
ciated with ACE inhibitors.10 Within the ARB class, there are 
differences in pharmacokinetic and pharmacologic properties 
that may translate into different therapeutic effects, including 
BP-lowering.
The newer ARB, azilsartan, is commercially available as 
40 mg and 80 mg oral tablets. The bioavailability of the drug 
is estimated at 60%, with peak plasma concentrations obtained 
at 1.5 to 3 hours. Azilsartan demonstrated a volume of dis-
tribution of approximately 16 L and is highly protein-bound 
(.99%). The half-life has been measured at 11 hours, and the 
major enzyme responsible for its metabolism is CYP2C9.11
Azilsartan, a prodrug, is a selective and insurmountable 
AT1 antagonist with evidence suggesting it not only has 
high binding affinity, but also has slow dissociation from 
the target receptor.12 Azilsartan has been shown in vitro to 
have a higher percentage of inhibition at human AT1 than 
olmesartan, telmisartan, valsartan, and irbesartan. In the same 
study, azilsartan also showed the greatest receptor binding 
after washout when compared to the other ARBs.12 These data 
suggest that azilsartan may bind more tightly and dissociate 
more slowly from the selective target AT1 than the compara-
tor ARBs. Clinically, azilsartan’s binding characteristics may 
allow for this drug to have greater BP-lowering effects and a 
longer duration of action compared to other ARBs.
The insurmountable, or tight-binding behavior, may be 
attributable to the presence of a carboxyl group as part of the 
ARB chemical structure. The ARBs with a carboxyl moiety 
and insurmountable binding include olmesartan, candesartan, 
and azilsartan.12 The carboxyl group is thought to be responsi-
ble for interaction with the amino acid lysine and provide tight 
binding to AT1. The carboxyl group may also be related to the 
beneficial decrease in hypertrophy exhibited by these ARBs. 
In addition to a carboxyl group, azilsartan also has a distinctive 
oxadiazolone group in place of the tetrazole ring that exists 
as part of the structure on other currently available ARBs. 
It is possible that the oxadiazolone structure in azilsartan 
allows azilsartan to bind more strongly to essential residues 
of the AT1. Tighter receptor binding, as has been shown with 
azilsartan, may be an advantageous characteristic since this 
binding would allow azilsartan to maintain its effects even 
when AngII levels increase.12 When ARBs are administered 
to patients, AngII levels are known to increase as a compen-
satory mechanism caused by AT1 inhibition during ARB 
treatment. Elevated AngII levels may theoretically displace 
ARBs from their receptor sites. ARBs with tighter binding 
characteristics may be less likely to be displaced resulting in 
greater therapeutic efficacy as compared to ARBs with less 
tight binding characteristics. Azilsartan’s unique structure and 
pharmacological properties may provide advantages in the 
treatment of hypertension compared to other ARBs.
Azilsartan versus other ARBs
As a monotherapy, azilsartan 80 mg once daily has been 
shown to be more effective in lowering systolic and trough 
BP than other ARBs at their highest approved doses. One trial 
compared increasing doses of azilsartan (20, 40, and 80 mg) 
to olmesartan 40 mg and placebo.13 The primary endpoint 
in this trial was a change in 24-hour mean ambulatory BP 
after 6 weeks of treatment in 1260 randomized essential 
hypertension patients. Clinic BP (measured 24 hours after 
previous dose) and percentage of responding patients were 
evaluated in this study. A “responder” was defined as a 
patient achieving systolic BP (SBP) of ,140 mmHg or 
a decrease of $20 mmHg. All BP was measured with an   
automated device. The trial excluded patients with estimated 
glomerular filtration rate (eGFR) , 30 mL/min and type I 
or poorly controlled type II diabetes. The 40 mg dose of 
azilsartan was shown to be n  oninferior to olmesartan. The 
difference of change in 24-hour mean SBP was -2.1 mmHg 
(95% confidence interval [CI]: -4.0–0.1; P = 0.038) greater 
with azilsartan 80 mg compared to olmesartan 40 mg. The 
results also showed a -2.7 mmHg greater decrease (95% 
CI: -5.3–0.1; P = 0.043) in clinical SBP with administration 
of azilsartan 80 mg compared to olmesartan. However, there 
was no significant difference in the amount of patients that 
achieved clinical response (57% azilsartan and 53% olm-
esartan; P = 0.402) between these two arms. Although not 
statistically significant, a subgroup analysis regarding patients 
with a body mass index (BMI) $ 30 kg/m2 showed a treat-
ment difference between azilsartan 80 mg and olmesartan 
40 mg of -2.7 mmHg (95% CI: -5.8–0.32) compared to a 
-1.7 mmHg difference in patients with a BMI , 30 (95% 
CI: -4.2–0.9). There was no difference in adverse effects 
between all treatment groups. In conclusion, azilsartan 
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showed a statistically significant decrease in SBP based on 
24-hour ambulatory BP and trough (clinical) BP.
A trial similar in patient population, timeline, and primary 
outcome to the previously discussed trial above, compared 
azilsartan 40 mg and 80 mg to placebo, olmesartan 40 mg, 
or valsartan 320 mg in 1175 randomized hypertensive 
patients.13,14 This study assessed the same endpoints of mean 
24-hour BP, clinical BP, and percentage of responding 
patients. All BP measurements were obtained using automated 
devices. Comparable to the previous trial, azilsartan 40 mg 
was shown to be noninferior to olmesartan, while azilsar-
tan 80 mg showed superiority to both of the highest doses 
approved for olmesartan and valsartan (difference in reduc-
tion of mean 24-hour SBP -2.5 mmHg, 95% CI: -4.4–0.6; 
-4.3 mmHg, 95% CI: -6.3–2.4, respectively). Azilsartan 
40 mg and 80 mg also had a greater reduction in clinical BP 
compared to olmesartan 40 mg and valsartan 320 mg (-14.6, 
-14.9, -11.4, and -9.5 mmHg, respectively; all P , 0.05). 
Unlike the previous trial, this trial found a significantly larger 
amount of “responders” in the azilsartan arm (58%) than the 
valsartan (49%) or olmesartan (49%) arms (P , 0.05). No dif-
ference was seen when comparing obese to nonobese patients, 
and all treatment arms showed similar adverse events.
The above trials demonstrated that azilsartan has greater 
efficacy in decreasing overall SBP and greater BP effects 
at the end of the dosing interval. The extent of azilsartan’s 
effects on SBP, although marginal, may prove to be clini-
cally significant as current guidelines discuss a decrease of 
cardiovascular events with SBP reductions of 2 mmHg.2 
In addition, it should be emphasized that azilsartan actually 
showed superiority to agents in the same class as opposed 
to merely demonstrating noninferiority. These findings sug-
gest azilsartan could be an innovative ARB that has distinct 
advantages over the other ARBs and these advantages may 
be related to its pharmacological profile.
Azilsartan–chlorthalidone 
combination
The combination of azilsartan–chlorthalidone is a novel 
combination agent because it is the first to combine an ARB 
with the long-acting diuretic, chlorthalidone. This fixed-dose 
combination (Edarbyclor®; Takeda Pharmaceutical, Osaka, 
Japan) was recently approved by the US Food and Drug 
Administration (FDA) on December 20, 2011 as 40/12.5 mg 
and 40/25 mg dosages. The first phase III trial to evaluate this 
combination was a randomized, double-blind, multicenter, 
6-week treatment study comparing two different doses of 
azilsartan (40 mg or 80 mg) combined with 25 mg chlortha-
lidone to 25 mg chlorthalidone monotherapy in essential 
hypertension patients.15 Baseline characteristics were not 
reported in the study. The results showed a statistical decrease 
in 24-hour mean SBP in both the azilsartan–chlorthalidone 
40/25 mg and 80/25 mg arms (-31.72 and -31.3 mmHg, 
respectively; P , 0.001) when compared to chlorthalidone 
alone (-15.85 mmHg). Similar results were seen when 
comparing mean diastolic pressure, mean daytime systolic 
pressure, and mean nighttime systolic pressure (  Figure 1). 
Another secondary outcome examined the difference 
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Figure 1 Change from baseline blood pressure measures at 6 weeks.
Notes: aP , 0.001 compared to chlorthalidone 25 mg daily, mean daytime systolic blood pressure was measured from 6 am to 10 pm, mean nighttime systolic blood pressure 
was measured from 12 am to 6 am, trough SBP was measured 22 to 24 hours after the dose was given.15
Abbreviations: AZL, azilsartan; CLD, chlorthalidone; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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between each treatment arm regarding trough SBP, defined 
as systolic measurement recorded 22 to 24 hours after dosing. 
The difference in trough SBP was statistically greater for 
both azilsartan combination arms compared to the chlortha-
lidone arm (40 mg: -14.04 mmHg, 95% CI: -17.13–10.94; 
80 mg: -13.48 mmHg, 95% CI: -16.58–10.37; P , 0.001, 
respectively). This trial displays that the combination of 
azilsartan–chlorthalidone is more effective at decreasing 
BP than chlorthalidone monotherapy. This study also dem-
onstrates azilsartan–chlorthalidone’s long-acting benefit by 
assessing the continued decrease in BP 22 to 24 hours after 
dosing. This trial did not show any statistical difference in BP 
effects between the different dosing regimens of azilsartan 
40 or 80 mg plus chlorthalidone.
In another trial only published in abstract form, several 
different fixed-dose azilsartan–chlorthalidone combinations 
were compared to different doses of both of the   monotherapies. 
This was an 8-week, randomized, double-blind trial in 1714 
hypertensive patients with a primary endpoint of change in 
trough SBP.16 Patients received either azilsartan placebo, 
20, 40, or 80 mg and chlorthalidone placebo, 12.5, or 25 mg 
either as monotherapy or in combination. There was no 
double-placebo arm. Baseline characteristics provided were 
mean age 57 years, 47% men, and 20% black patients, with 
no differences reported among the treatment groups. All six 
of the combination therapy arms resulted in a significantly 
greater decrease in trough SBP when compared to their 
comparative monotherapy components (Table 1). As seen 
in Table 1, there was no greater benefit seen when compar-
ing azilsartan–chlorthalidone 40/25 mg to 80/25 mg. There 
was a dose-dependent increase in therapy discontinuation 
and serum creatinine seen with azilsartan–chlorthalidone. 
Interestingly, it was noted in the study that the addition of 
azilsartan seemed to attenuate the chlorthalidone-related 
hypokalemia, but no data was provided in the abstract.16
Another published abstract examined the fixed-dose com-
bination of azilsartan–chlorthalidone 20/12.5 mg titrated to 
40/25 mg (AZL40-CLD25), 40/12.5 mg titrated to 80/25 mg 
(AZL80-CLD25), and olmesartan–hydrochlorothiazide 
20/12.5 mg titrated to 40/25 mg (OLM40-HCTZ25) in 1085 
patients with hypertension.17 Patients were only titrated to 
the higher dose if their SBP was not at goal by week 4. This 
was an 8-week, randomized, double-blind trial. Baseline 
characteristics included 52% men, 26.7% blacks, 17.3% 
diabetics, a mean age of 56 years, and a BMI of 31.8 kg/m2. 
Both azilsartan–chlorthalidone combinations decreased clini-
cal BP (seated trough BP) significantly more than olm-
esartan/hydrochlorothiazide (AZL40-CLD25 = -33.0 and 
AZL80-CLD25 = -34.1 vs OLM40-HCTZ25 = -26.9 mmHg; 
P , 0.001). A greater reduction in 24-hour mean SBP was 
also seen with both azilsartan–chlorthalidone combina-
tions (-26.4 and -27.9 versus -20.7 mmHg; P , 0.001) 
Similarly, there was also less titration to higher doses in the 
azilsartan–chlorthalidone arms (38.4% and 34.7%) than in 
the olmesartan/hydrochlorothiazide group (51.7%). Adverse 
events causing either temporary or permanent discontinuation 
of therapy occurred in 6.2% and 9.5% of the azilsartan–chlo-
rthalidone arms and 3.1% of the olmesartan–hydrochlorothiaz-
ide group (no P values were provided in the abstract).17 These 
trials demonstrate a greater decrease in mean and trough SBP 
with the azilsartan–chlorthalidone combination.
Chlorthalidone versus 
hydrochlorothiazide
Current guidelines suggest thiazide-type diuretics as first-line 
treatment in hypertension and list several options, but do 
not distinguish preference between any agents.2   Generally 
chlorthalidone and hydrochlorothiazide are viewed as inter-
changeable, but their effects on cardiovascular events have 
never been compared in a prospective trial. Most of the 
major clinical trials involving a thiazide-type diuretic have 
included either chlorthalidone or hydrochlorothiazide, yet 
hydrochlorothiazide is much more commonly prescribed 
and included in combination products.18 The debate regard-
ing possible differences in clinical benefit between the two 
agents has been an increasing topic of interest.
Though several differences between the drugs are 
known, it has not been determined which, or if any, could 
Table 1 Change in trough SBP of combinations when compared to the monotherapy components at week 8
LSM SBP reduction (mmHg) No azilsartan Azilsartan 20 mg Azilsartan 40 mg Azilsartan 80 mg
No chlorthalidone – -12.1 -12.8 -15.1
Chlorthalidone 12.5 mg -12.7 -22.9a,b -24.4a,b -26.3a,b
Chlorthalidone 25 mg -15.9 -26.3a,b -29.8a,b -28.0a,b
Notes: aP , 0.001 compared to chlorthalidone component; bP , 0.001 compared to the azilsartan component. Copyright © 2011. Reprinted with permission from John 
Wiley and Sons. American Society of Hypertension. Twenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 182]. J Clin Hypertens. 2011;13:12–163. 
Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00459.x/abstract. Accessed January 2011.16
Abbreviations: LSM, least squares mean; SBP, systolic blood pressure.
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cause a change in patient outcomes. Structural differences 
exist between chlorthalidone and hydrochlorothiazide. 
  Hydrochlorothiazide belongs to the drug class benzothia-
diazines, simply known as thiazides. Drugs in this class all 
share a similar dual-ring structure to the thiazide diuretic 
prototype, chlorothiazide. Chlorthalidone is commonly 
referred to as a thiazide, but is more properly addressed 
as a thiazide-type diuretic. Though commonalities exist, 
chlorthalidone is molecularly unique in structure.18 It is also 
known that chlorthalidone has a longer half-life (40 hours) 
compared to hydrochlorothiazide (6–9 hours). Some stud-
ies found that chlorthalidone concentrates in erythrocytes. 
The slow release of the drug from these erythrocytes is one 
explanation for chlorthalidone’s long half-life.18 A review of 
available studies suggests that chlorthalidone 25 mg daily is 
roughly equivalent to hydrochlorothiazide 50 mg daily. This 
ratio has been found in other analyses as well.18
Although no prospective, randomized trials assessing car-
diovascular outcomes between the two have been conducted, 
evidence indicates that chlorthalidone may be superior to 
hydrochlorothiazide.19 The Multiple Risk Factor Intervention 
Trial (MRFIT) was first to propose a clinical benefit with 
chlorthalidone compared to hydrochlorothiazide.20 MRFIT 
was a large randomized primary prevention trial assessing 
the efficacy of a multifactor intervention program, which 
included dietary advice, smoking cessation counseling, and 
hypertension treatment compared to usual care (UC). Patients 
in the study could receive chlorthalidone or hydrochlorothi-
azide for hypertensive therapy. Approximately 5 years after 
randomization, the diuretic treatment protocol was changed to 
replace treatment with hydrochlorothiazide to chlorthalidone 
due to a 44.1% higher coronary heart disease (CHD) mortal-
ity in clinics predominantly prescribing hydrocholorothiazide 
compared to the UC group (P = 0.23), whereas the clinics 
predominantly prescribing chlorthalidone had a -58.2% 
(reduction) in CHD mortality compared to UC.21 After the 
change was instituted, the rate of CHD mortality in the previ-
ously predominant hydrochlorothiazide clinics decreased to 
–7.9% when compared to UC.21
A retrospective, cohort analysis of the MRFIT data was 
completed to evaluate the cardiovascular endpoints between 
patients taking the two different drugs.22 The results showed 
a 21% lower risk of cardiovascular events in patients taking 
chlorthalidone compared to hydrochlorothiazide (hazard 
ratio [HR] 0.79; 95% CI: 0.68–0.92; P = 0.0016). Second-
ary outcome measures showed that patients prescribed 
chlorthalidone had a significantly lower SBP, total choles-
terol, and low-density lipoprotein (LDL) compared with 
hydrochlorothiazide. In contrast to these optimistic results, 
the study also revealed significantly lower serum potassium 
and higher uric acid with chlorthalidone, but these did not 
seem to increase events in this group. A small, randomized, 
prospective study evaluated the efficacy of chlorthalidone to 
hydrochlorothiazide on ambulatory and trough BP.23 This was 
a force titration study that compared chlorthalidone 25 mg 
daily to hydrochlorothiazide 50 mg daily, doses which have 
been shown in other literature to be relatively equivalent.18 
Though underpowered, the results revealed a trend towards 
greater reduction in mean SBP with chlorthalidone than with 
hydrochlorothiazide after 8 weeks (-12.4 versus -7.4 mmHg, 
P = 0.054). The difference was attributed to chlorthalidone’s 
greater effect on nighttime SBP (-13.5 versus -6.4 mmHg; 
P = 0.009). No significant differences in serum potassium 
were noted between the two groups (-0.5 versus -0.4 mEq/L; 
P = 0.76).23 These trials support the idea that chlorthalidone 
is a more potent and longer lasting antihypertensive medica-
tion compared to hydrochlorothiazide. The MRFIT cohort 
analysis also supplies additional information regarding 
its effects on the metabolic profile, which may reveal the 
mechanism of cardiovascular benefit when compared to 
hydrochlorothiazide.
Combination therapy versus 
monotherapy
Initial combination therapy is recommended for many 
hypertensive patients requiring a .20 mmHg decrease in 
SBP to reach goal.2 As seen in the ALLHAT trial, 63% of 
the study population was eventually on two or more drugs; 
and at the end of 5 years only 66% had achieved controlled 
BP.8 Numerous newer trials have also shown high rates of 
patients requiring more than one drug for BP management; 
such as INVEST (80%), ASCOT-BPLA (78%), and LIFE 
(88%).3,24,25 Since a large number of hypertensive patients 
requires more than one drug to control their hypertension, 
many trials have examined the benefit of combinations of 
antihypertensive medications as well as the benefit of com-
bination therapy as initial treatment.
Suggested benefits of combination therapy compared 
to monotherapy include increased BP control by differ-
ent mechanisms of action, lower dosing requirements, 
and fewer adverse events. In a study comparing losartan 
50 mg plus barnidipine and losartan 100 mg monother-
apy, no significant difference in amount of BP decrease 
was seen; however there was a higher rate of BP goal 
obtainment with the combination arm (82.1% versus 56.0%; 
P = 0.044).26 Both treatment arms were well tolerated. The 
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ACCELERATE trial, examined initial combination therapy 
(aliskiren–amlodipine)   compared to initial monotherapy 
of each component followed by subsequent combination 
therapy in all arms.27 The initial combination therapy had 
a greater decrease in SBP (-7.4 mmHg versus aliskiren 
and -5.5 mmHg versus amlodipine; P , 0.0001) than 
either monotherapy. After 24 weeks and all patients 
advanced to combination, the initial monotherapy groups’ 
SBPs decreased and there ceased to be a significant dif-
ference between the three arms. This trial also demonstrated 
balanced adverse events between all groups.27
The prompter achievement of BP goal may also be a 
benefit of initial combination therapy opposed to initial 
monotherapy later progressing to combination therapy. 
Results from the VALUE trial, comparing a valsartan-based 
BP regimen to a amlodipine-based BP regimen, suggest that 
obtaining BP control within the first month of treatment is 
correlated to a lower rate of cardiovascular events.28 The 
previously discussed ACCELERATE trial showed cessation 
of a significant difference between all combination therapy 
arms at the end of the study period (24 weeks), yet the SBP 
in the initial combination treatment arm remained lower 
than either of the progression groups.27 A large, case-control 
study showed an 11% decrease in cardiovascular events 
when patients receiving antihypertensive medications were 
initiated on combination therapy instead of monotherapy.29 
An important finding in this study was that no difference in 
events was seen between continuous monotherapy and when 
monotherapy was switched to combination therapy (Table 2). 
The only scenario that showed significant decrease in car-
diovascular events was the continuous combination therapy 
arm (odds ratio [OR] 0.74; 95% CI: 0.65–0.85). These data 
suggest that the best outcomes may be achieved when com-
bination therapy is initially started in hypertensive patients.
Another advantage to consider with combination 
therapy is the added benefit of fixed combination drugs. 
Fixed combination drugs have the ability to simplify 
complex medication regimens, increase adherence, and be 
more cost effective than their separate parts. Most patients 
require combination therapy for treatment of hyperten-
sion, and initiation with a fixed combination drug, such as 
azilsartan–chlorthalidone, can be clinically beneficial and 
more convenient.
Conclusion
Azilsartan–chlorthalidone is a unique combination drug and 
does have a place in the treatment of hypertension. As the 
use of ARBs is becoming more popular, azilsartan sets itself 
apart from the class by demonstrating greater SBP-lowering 
and longer-lasting hypertensive effects. The chlorthalidone 
component of the drug also makes this fixed combination 
distinctive. Chlorthalidone’s suggested superiority over 
hydrochlorothiazide could add to the clinical benefit of this 
regimen. Additionally a fixed-combination drug can offer 
the benefit of increasing the amount of patients initiated on 
combination therapy, leading to patients obtaining their BP 
goals faster. The effects of azilsartan–chlorthalidone fixed 
combination have yet to be tested in large, morbidity and 
mortality trials, but the current data are promising.
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